AUA 2022: Prognostic Significance of Risk Stratification in CHAARTED and LATITUDE Studies Among Japanese Men with CRPC

(UroToday.com) The 2022 American Urological Association (AUA) Annual Meeting included a session on advanced prostate cancer and a presentation by Dr. Masaki Shiota discussing prognostic significance of risk stratification in CHAARTED1 and LATITUDE2 studies among Japanese men with castration-resistant prostate cancer (CRPC). The CHAARTED and LATITUDE trials previously demonstrated a significant survival benefit of docetaxel and abiraterone versus ADT alone for hormone-sensitive prostate cancer, respectively. In this study, Dr. Shiota and colleagues examined the impact of the risk stratification criteria used in the CHAARTED and LATITUDE trials on the prognosis of CRPC. They also tested whether these risk stratification criteria could help in selecting effective initial treatment for CRPC.


Japanese patients with CRPC who were treated with docetaxel or androgen receptor pathway inhibitors such as abiraterone acetate or enzalutamide between 2014 and 2018 were included in this study. Clinicopathological factors, progression-free survival, and overall survival were investigated.

Of 215 patients, 110 men (51.2%) and 93 men (43.3%) were grouped as high volume by CHAARTED criteria and high risk by LATITUDE criteria, respectively. Median progression-free survival was 10.3/4.5 months (p < 0.0001) for low/high volume (CHAARTED criteria) and 9.9/4.8 months (P=0.0032) for low/high risk (LATITUDE criteria):

AUA_Shiota-0.jpg

The median overall survival was 44.8/17.4 months (P <0.0001) for low/high volume (CHAARTED criteria) and 37.4/17.4 months (p = 0.0011) for low/high risk (LATITUDE criteria):

AUA_Shiota-1.jpg

The prognostic impact of CHAARTED and LATITUDE criteria was comparable between androgen receptor pathway inhibitors and docetaxel as first-line treatment for CRPC.

Dr. Shiota concluded his presentation by emphasizing that the CHAARTED and LATITUDE criteria were prognostic, but not predictive factors for CRPC. 

Presented by: Masaki Shiota, MD, PHD, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Written by: Zachary Klaassen, MD, MSc – Urologic Oncologist, Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia, @zklaassen_md on Twitter during 2022 American Urological Association (AUA) Annual Meeting, New Orleans, LA, Fri, May 13 – Mon, May 16, 2022.

References:

  1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-746.
  2. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-360.
email news signup